ArticleBMC pulmonary medicine2025
Time to sputum culture conversion and associated factors in multidrug-resistant tuberculosis patients in Southwestern Oromia, Ethiopia: a ten-year retrospective follow-up study.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSputum culture conversion is an important predictor of treatment response and patient outcome in pulmonary multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB). However, the determinants of time to culture conversion and its association with treatment regimens among MDR/RR-TB patients in Southwestern Oromia remain poorly understood. This study aimed to determine the time to initial sputum culture conversion and associated factors among pulmonary MDR/RR-TB patients in Southwestern Oromia, Ethiopia.
methodsWe conducted a retrospective follow-up study on 168 MDR/RR-TB patients who had initiated treatment and followed up between 2013 and 2023 at centers in the Southwestern Oromia region of Ethiopia. A semi-structured data collection tool was used to extract demographic, clinical and bacteriological data. The median time to sputum culture conversion was analysed using Kaplan‒Meier survival curves. Bivariate and multivariate Cox proportional hazards regression analyses were employed to identify factors associated with delayed time to sputum culture conversion. A p-value less than 0.05 was considered statistically significant.
resultsOf the 168 participants, 85.7% (144) achieved culture conversion during a total follow-up of 397.8 person-months. Among those converted, 48.6% (70/144) achieved conversion within two months, 42.4% (61/144) within three to four months, and 9% (13/144) after four months of treatment. The median time to sputum culture conversion was 62 days (IQR: 32-92). The median time to culture conversion was longer for smear-positive samples (63 days, IQR: 32-93 days) than for smear-negative samples (59 days, IQR: 30-90 days, chi
conclusionThe median time to initial sputum culture conversion was 62 days, which was lower than the 4-month threshold considered a potential indicator of treatment failure according to the World Health Organization. MDR/RR-TB patients with HIV coinfection, higher baseline smear grades and those on longer treatment regimens were shown to have a delayed time to culture conversion. Attention should be given to these patients during their MDR/RR-TB treatment course to reduce delays in culture conversion and improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.